C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target

被引：3

作者：

Lumsden, Natalie G. ^{[1
]}

Khambata, Rayomand S. ^{[2
]}

Hobbs, Adrian J. ^{[2
]}

机构：

[1] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia

[2] UCL, London WC1E 6BT, England

来源：

CURRENT PHARMACEUTICAL DESIGN | 2010年 / 16卷 / 37期

基金：

英国惠康基金;

关键词：

Natriuretic peptide; endothelium; vasodilatation; platelet; leukocyte; cardiovascular disease; VASCULAR SMOOTH-MUSCLE; ENDOTHELIN-RECEPTOR ANTAGONIST; NITRIC-OXIDE PRODUCTION; GUANYLYL CYCLASE; SHEAR-STRESS; ENDOCHONDRAL OSSIFICATION; NEOINTIMAL HYPERPLASIA; PULMONARY VASODILATION; EXTRACELLULAR DOMAIN; CARDIAC-HYPERTROPHY;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Natriuretic peptides play a fundamental role in cardiovascular homeostasis by modulation of fluid and electrolyte balance and vascular tone. C-type natriuretic peptide (CNP) represents the paracrine element of the natriuretic peptide axis which complements the endocrine actions of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). CNP is produced by the endothelium and the heart and appears to play a prominent role in vascular and cardiac function, both physiologically and pathologically. This provides a rationale for the therapeutic potential of pharmacological interventions targeted to CNP signalling. This article provides an overview of the biology and pharmacology of CNP, with emphasis on the cardiovascular system, and discusses pathologies in which drugs designed to manipulate CNP signalling maybe of clinical benefit.

引用

页码：4080 / 4088

页数：9

共 166 条

[1] Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor [J].

Ahluwalia, A ;

Hobbs, AJ .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (03) :162-167

[2] Variable number of tandem repeat of the 5′-flanking region of type-C human natriuretic peptide receptor gene influences blood pressure levels in obesity-associated hypertension [J].

Aoi, N ;

Soma, M ;

Nakayama, T ;

Rahmutula, D ;

Kosuge, K ;

Izumi, Y ;

Matsumoto, K .

HYPERTENSION RESEARCH, 2004, 27 (10) :711-716

[3] Basic Science of Pulmonary Arterial Hypertension for Clinicians New Concepts and Experimental Therapies [J].

Archer, Stephen L. ;

Weir, E. Kenneth ;

Wilkins, Martin R. .

CIRCULATION, 2010, 121 (18) :2045-U175

[4] Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension [J].

Baliga, Reshma S. ;

Zhao, Lan ;

Madhani, Melanie ;

Lopez-Torondel, Belen ;

Visintin, Cristina ;

Selwood, David ;

Wilkins, Martin R. ;

MacAllister, Raymond J. ;

Hobbs, Adrian J. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (08) :861-869

[5] Gender and relaxation to C-type natriuretic peptide in porcine coronary arteries [J].

Barber, DA ;

Burnett, JC ;

Fitzpatrick, FA ;

Sieck, GC ;

Miller, VM .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (01) :5-11

[6] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[7]

BENNETT BD, 1991, J BIOL CHEM, V266, P23060

[8] Recent advances in natriuretic peptides in congestive heart failure [J].

Boerrigter, G ;

Burnett, JC .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (06) :643-652

[9] LONG-TERM VEIN GRAFT PATENCY [J].

BOURASSA, MG .

CURRENT OPINION IN CARDIOLOGY, 1994, 9 (06) :685-691

[10] Relaxant effect of C-type natriuretic peptide involves endothelium and nitric oxide-cGMP system in rat coronary microvasculature [J].

Brunner, F ;

Wölkart, G .

CARDIOVASCULAR RESEARCH, 2001, 51 (03) :577-584

← 1 2 3 4 5 6 7 8 9 10 →